- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statements (Form S-3 Nos. 333-204914 and 333-225225) of OncoMed Pharmaceuticals, Inc. and
(2) Registration Statements (Form S-8 Nos. 333-190932, 333-194867, 333-201707, 333-210081, 333-215409 and 333-222411) pertaining to the 2013 Equity Incentive Award Plan, the 2013 Employee Stock Purchase Plan, and the 2004 Stock Incentive Plan of OncoMed Pharmaceuticals, Inc.
of our reports dated March 7, 2019, with respect to the financial statements of OncoMed Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of OncoMed Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of OncoMed Pharmaceuticals, Inc. for the year ended December 31, 2018.
/s/ Ernst & Young LLP
Redwood City, California
March 7, 2019